Latest News on CRSP

Financial News Based On Company


Advertisement
Advertisement

InvestingPro Fair Value flagged CRISPR as overvalued before 47% drop By Investing.com

https://www.investing.com/news/investment-ideas/investingpro-fair-value-flagged-crispr-as-overvalued-before-47-drop-93CH-5032254
InvestingPro's Fair Value analysis identified CRISPR Therapeutics (CRSP) as significantly overvalued in February 2024 at $76.44 per share. By November 2026, the stock had dropped 47% to $40.37, validating the analysis. The platform's methodology combines multiple valuation approaches to help investors identify mispriced securities and avoid overvalued stocks.

CRISPR Therapeutics CEO Sam Kulkarni says investors are "sleeping on gene editing" as one-shot therapy takes on siRNA

https://finance.biggo.com/news/43b9ac5338dae9a6
CRISPR Therapeutics CEO Sam Kulkarni argues that gene editing is transitioning from a scientific endeavor to a commercial product, with Casgevy generating significant revenue and a pipeline of promising assets. Kulkarni asserts that gene editing's one-and-done approach will ultimately outperform chronic dosing economically, even as the company diversifies into siRNA assets to generate short-term catalysts. He highlights the mechanistic and health-economic advantages of gene editing, suggesting that payers may prefer upfront costs over decades of chronic treatment.

Two investors report owning 4.52 million CRISPR Therapeutics (CRSP) shares.

https://www.stocktitan.net/sec-filings/CRSP/schedule-13g-a-crispr-therapeutics-ag-amended-passive-investment-disc-09f91b1838da.html
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have reported beneficial ownership of a combined 4,519,261 common shares in CRISPR Therapeutics AG (CRSP), representing 4.7% of the class, as of September 30, 2026. Orbis holds the majority with 4,501,782 shares, while Allan Gray Australia Pty Ltd holds 17,479 shares. Both entities assert sole voting and dispositive power over their respective shares and explicitly state they are not acting as a group under Section 13(d)(3) of the Securities Exchange Act of 1934.

ARK and Catherine D. Wood report a CRISPR Therapeutics (CRSP) stake; ARK Innovation ETF exceeds 5%.

https://www.stocktitan.net/sec-filings/CRSP/schedule-13g-a-crispr-therapeutics-ag-amended-passive-investment-disc-594bebccff39.html
ARK Investment Management LLC and Catherine D. Wood have reported a beneficial ownership of 10,056,844 shares, or 10.40% of CRISPR Therapeutics AG (CRSP) common stock, as of September 30, 2026. The filing, an Amendment No. 14 to Schedule 13G/A, indicates ARK's sole voting power over 9,466,222 shares and shared voting power over 143,106 shares, while Wood reports shared voting power over 9,609,328 shares. ARK Innovation ETF is identified as a client with an interest exceeding 5%.

Crispr Therapeutics stock hits 52-week low at $44.10

https://www.investing.com/news/company-news/crispr-therapeutics-stock-hits-52week-low-at-4410-93CH-5022280
CRISPR Therapeutics stock hit a 52-week low of $44.01, reflecting a 12% drop over the past year due to a turbulent market. Despite its overvalued status according to InvestingPro, analysts anticipate sales growth, with varied price targets from Wells Fargo, Piper Sandler, Citizens, and H.C. Wainwright based on recent financial results and promising clinical trial data for CTX310 and Casgevy.
Advertisement

Form 144 CRISPR THERAPEUTICS AG For: 11 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-crispr-therapeutics-ag-for-11-november-93CH-4976039
This article announces the filing of Form 144 for CRISPR THERAPEUTICS AG on November 11. It's a brief financial news update from Investing.com, providing basic information about the company and the filing event. The content also includes various market data, indices, and popular articles, which are not directly related to the Form 144 announcement itself.

CRISPR Therapeutics Highlights Substantial Lipid Reductions with Investigational Gene Editing Therapy

https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/11/63113462/crispr-therapeutics-highlights-substantial-lipid-reductions-with-investigational-gene-editing-therapy
CRISPR Therapeutics AG presented clinical data for its investigational gene editing therapy, CTX310, showing significant reductions in lipid levels for patients with severe hypertriglyceridemia. A single course of treatment led to a 65% mean reduction in ANGPTL3 and a 63% mean drop in triglycerides at Day 30, along with favorable safety results. William Blair reiterated an Outperform rating, noting the data exceeded expectations and indicated preliminary regulatory buy-in.

Piper Sandler reiterates CRISPR Therapeutics stock rating at overweight

https://www.investing.com/news/analyst-ratings/piper-sandler-reiterates-crispr-therapeutics-stock-rating-at-overweight-93CH-5015582
Piper Sandler has reiterated an Overweight rating and a $110.00 price target for CRISPR Therapeutics (NASDAQ:CRSP) following positive clinical data presentations for CTX310 and zugo-cel at recent medical meetings. The company also reported Q3 2026 CASGEVY sales of $99 million, with Piper Sandler projecting $327 million for the full year. Despite a recent net loss per share and concerns about overvaluation, the company's strong cash position supports its pipeline development.

More than 5% of CRISPR Therapeutics (CRSP) is in State Street's reported passive stake.

https://www.stocktitan.net/sec-filings/CRSP/schedule-13g-crispr-therapeutics-ag-passive-investment-disclosure-5-ed1adc5a8396.html
State Street Corporation has reported a beneficial ownership of 4,994,047 common shares in CRISPR Therapeutics AG (CRSP), representing 5.2% of the class as of September 30, 2026. This Schedule 13G filing indicates shared voting power over 4,737,614 shares and shared dispositive power over all 4,994,047 shares, with no sole voting or dispositive power. The filing classifies this as a passive investment, stating the securities were acquired in the ordinary course of business without the purpose of influencing control.

Form SCHEDULE 13G CRISPR Therapeutics AG Filed by: STATE STREET CORP

https://www.streetinsider.com/SEC+Filings/Form+SCHEDULE+13G+CRISPR+Therapeutics+AG+Filed+by%3A+STATE+STREET+CORP/27318196.html
STATE STREET CORPORATION has filed a Schedule 13G form regarding its ownership in CRISPR Therapeutics AG. The filing indicates that State Street Corporation beneficially owns 4,994,047 shares, representing 5.2% of the common stock of CRISPR Therapeutics AG. This ownership includes shared voting power over 4,737,614 shares and shared dispositive power over all 4,994,047 shares, with the filing made on November 9, 2026.
Advertisement

CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

https://markets.businessinsider.com/news/stocks/crispr-therapeutics-to-present-at-the-2026-jefferies-global-healthcare-conference-1036742552
CRISPR Therapeutics announced that its senior management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on November 17, 2026. A live webcast will be available on the company's website, with a replay archived for 14 days. CRISPR Therapeutics is a biopharmaceutical company focused on gene-based medicines, known for the first CRISPR-based therapy, CASGEVY.

CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026

https://www.quantisnow.com/insight/crispr-therapeutics-presents-phase-1b-data-for-ctx310-demonstrating-reductions-6780673
CRISPR Therapeutics presented positive Phase 1b data for its gene editing therapy, CTX310, showing significant reductions in ANGPTL3 and triglycerides in patients with severe hypertriglyceridemia. The therapy demonstrated a mean 65% reduction in ANGPTL3 and a 63% reduction in triglycerides at Day 30, with no treatment-related serious adverse events. CTX310 has also received RMAT designations from the FDA for severe hypertriglyceridemia and elevated LDL-C.

The CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Sales Forecasts

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/the-crispr-therapeutics-ag-nasdaqcrsp-analysts-have-been-tri
CRISPR Therapeutics AG (NASDAQ:CRSP) analysts have significantly revised down their near-term revenue forecasts for 2027, now expecting US$133m, a 430% improvement from the last 12 months, but a notable cut from previous estimates. Simultaneously, loss per share forecasts have increased to US$3.57. Despite the weaker earnings outlook, the consensus price target remains unchanged, suggesting analysts don't anticipate a long-term impact on valuation.

CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases

https://www.quantisnow.com/insight/crispr-therapeutics-provides-update-on-zugocabtagene-geleucel-zugo-cel-in-refractory-6779794
CRISPR Therapeutics has provided an early update on its gene-edited CAR-T therapy, zugo-cel, for refractory rheumatologic autoimmune diseases. Initial Phase 1 trial data presented at ACR Convergence 2026 showed positive responses in systemic sclerosis (83% at Month 3) and idiopathic inflammatory myopathy (100% improved), with no severe side effects reported. The study is still in early stages with small sample sizes, and no regulatory or commercial timelines have been announced yet.

Pekin Hardy Strauss Inc. Makes New $1.48 Million Investment in CRISPR Therapeutics AG $CRSP

https://www.marketbeat.com/instant-alerts/filing-pekin-hardy-strauss-inc-makes-new-148-million-investment-in-crispr-therapeutics-ag-crsp-2026-11-07/
Pekin Hardy Strauss Inc. has made a new $1.48 million investment in CRISPR Therapeutics AG, acquiring 26,775 shares in the third quarter. Despite a wider-than-expected quarterly loss and lower revenue than consensus estimates, CRISPR Therapeutics saw its revenue increase 1,311% year over year. Institutional investors collectively own 69.2% of the stock, while insiders sold 93,558 shares worth approximately $4.88 million in the last 90 days.
Advertisement

Form 144 CRISPR THERAPEUTICS AG For: 6 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-crispr-therapeutics-ag-for-6-november-93CH-4966156
This article announces the filing of Form 144 by CRISPR THERAPEUTICS AG on November 6th. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The article does not provide further details on the specific transactions but notes the company's stock symbol CRSP.

Form 4 CRISPR Therapeutics AG: Sivakesava Sakhamuri (Chief Technical Officer) For: 4 November

https://ng.investing.com/news/stock-market-news/form-4-crispr-therapeutics-ag-sivakesava-sakhamuri-chief-technical-officer-for-4-november-93CH-2791622
This article reports on a Form 4 filing for CRISPR Therapeutics AG, detailing a transaction involving Sivakesava Sakhamuri, the Chief Technical Officer, on November 4th. Form 4 filings are regulatory documents that disclose changes in the ownership of securities by a company's officers, directors, and principal shareholders. The article notes the stock symbol CRSP, which had a positive change of 3.11% at the time of publication.

An officer proposes selling CRISPR Therapeutics (CRSP) shares, including 64,578 from an option exercise.

https://www.stocktitan.net/sec-filings/CRSP/144-crispr-therapeutics-ag-sec-filing-253020824a8f.html
Raju Prasad, an officer at CRISPR Therapeutics AG (CRSP), has proposed selling 79,393 common shares with an aggregate market value of $3,960,183.20. The proposed sale, dated November 6, 2026, includes 64,578 shares obtained from a stock option exercise on the same day. Morgan Stanley Smith Barney LLC is listed as the broker for this transaction.

Form 144 CRISPR THERAPEUTICS AG For: 6 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-crispr-therapeutics-ag-for-6-november-93CH-4940630
This article announces the filing of Form 144 for CRISPR THERAPEUTICS AG (CRSP) on November 6, 2026. Form 144 indicates an intent to sell restricted securities, providing transparency regarding potential insider sales. The article also notes a 3.11% increase in CRSP stock.

Form 4 CRISPR Therapeutics AG: Sivakesava Sakhamuri (Chief Technical Officer) For: 4 November

https://ca.investing.com/news/stock-market-news/form-4-crispr-therapeutics-ag-sivakesava-sakhamuri-chief-technical-officer-for-4-november-93CH-4940616
This article reports on a Form 4 filing for CRISPR Therapeutics AG, specifically noting insider transactions by Sivakesava Sakhamuri, the Chief Technical Officer, on November 4th. The filing indicates a change in ownership for the company's stock, CRSP.
Advertisement

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

https://uk.finance.yahoo.com/news/crispr-therapeutics-ag-crsp-trending-130002698.html
This article from Zacks Equity Research analyzes CRISPR Therapeutics AG (CRSP), a stock gaining attention from Zacks.com visitors. It delves into factors influencing its near-term performance, including earnings estimate revisions, projected revenue growth, recent financial results, and valuation. The analysis concludes with a Zacks Rank #3 (Hold) for CRSP, suggesting it may perform in line with the broader market.

Earnings Update: CRISPR Therapeutics AG (NASDAQ:CRSP) Just Reported And Analysts Are Trimming Their Forecasts

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/earnings-update-crispr-therapeutics-ag-nasdaqcrsp-just-repor
CRISPR Therapeutics AG (NASDAQ:CRSP) recently reported disappointing quarterly results, missing revenue expectations by 24% and experiencing a 15% larger loss per share than anticipated. Following these results, analysts have significantly trimmed their 2027 revenue forecasts and increased their loss per share estimates for the company. The average price target for CRSP also fell by 13% to US$74.33, reflecting a less optimistic outlook on the company's valuation despite expectations for faster future growth compared to its past performance and the wider industry.

Crispr Therapeutics AG (CRSP) Receives a Hold from RBC Capital

https://www.theglobeandmail.com/investing/markets/stocks/CRSP/pressreleases/8662116/crispr-therapeutics-ag-crsp-receives-a-hold-from-rbc-capital/
RBC Capital analyst Luca Issi maintained a Hold rating on Crispr Therapeutics AG (CRSP) with a $50.00 price target. This follows a similar Hold rating from UBS, though Piper Sandler reiterated a Buy rating on the stock. Corporate insider sentiment for CRSP is negative, with an increase in insider selling observed over the past quarter.

CRISPR Therapeutics to Present Clinical Data from Zugo-cel

https://www.globenewswire.com/news-release/2026/11/04/3395391/0/en/crispr-therapeutics-to-present-clinical-data-from-zugo-cel-in-large-b-cell-lymphoma-at-the-68th-american-society-of-hematology-ash-annual-meeting-and-exposition.html
CRISPR Therapeutics announced that clinical data from its Phase 1/2 trial of zugocabtagene geleucel (zugo-cel) for relapsed or refractory large B-cell lymphoma will be presented at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2026. Zugo-cel is an investigational allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy. The company will share dose-dependent efficacy results from the trial during an oral presentation.

CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates

https://www.tradingview.com/news/zacks:807a1545a094b:0-crsp-s-q3-loss-wider-than-expected-sales-beat-estimates/
CRISPR Therapeutics (CRSP) reported a wider-than-expected loss of $1.15 per share for Q3 2026, though its total revenues of $12.7 million surpassed estimates, driven by strong collaboration revenues. The company continues to see robust sales momentum for its gene therapy, Casgevy, approved for sickle cell disease and beta thalassemia, and is advancing a diverse pipeline with several clinical updates anticipated by year-end. Despite the loss, CRSP maintains a strong cash position to fund its R&D efforts.
Advertisement

Form 8K CRISPR THERAPEUTICS AG For: 2 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-crispr-therapeutics-ag-for-2-november-93CH-4950363
The article reports that CRISPR THERAPEUTICS AG filed a Form 8K on November 2nd. This filing is a standard requirement for public companies to announce significant events that shareholders should know about. The brief piece, published by Investing.com, provides no further details about the content of the filing.

CRISPR Therapeutics AG Initial Statement of Beneficial Ownership

https://www.stocktitan.net/sec-filings/CRSP/form-3-crispr-therapeutics-ag-initial-statement-of-beneficial-ownersh-1af8a0eb6ffd.html
CRISPR Therapeutics AG (CRSP) has filed an Initial Statement of Beneficial Ownership of Securities (Form 3) with the SEC. The filing indicates that Sivakesava Sakhamuri, the newly appointed Chief Technical Officer, has no beneficial ownership of securities at the time of the statement. This form is a standard requirement for new officers of publicly traded companies.

CRISPR Therapeutics 3Q 2026: Revenue $12.7M, Net loss $111.4M, EPS $(1.15) — 10-Q Summary

https://www.tradingview.com/news/tradingview:959850b33bdcf:0-crispr-therapeutics-3q-2026-revenue-12-7m-net-loss-111-4m-eps-1-15-10-q-summary/
CRISPR Therapeutics (CRSP) reported third-quarter 2026 revenue of $12.7 million, a significant increase from $0.9 million a year prior, largely due to deferred Vertex collaboration revenue. The company's net loss widened to $111.4 million, though diluted loss per share narrowed to $(1.15). CRISPR Therapeutics also highlighted progress in its clinical trials for CTX310, CTX340, CTX460, and zugo-cel, and expects its cash resources to cover operations for at least 24 months.

Form 8K CRISPR THERAPEUTICS AG For: 2 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-crispr-therapeutics-ag-for-2-november-93CH-4923203
CRISPR THERAPEUTICS AG (CRSP) filed a Form 8K on November 2, 2026. The article from Investing.com announces this filing, noting the company's stock symbol and a 3.56% increase. This news is relevant for investors tracking company disclosures and market performance.

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

https://www.globenewswire.com/news-release/2026/11/02/3393703/0/en/crispr-therapeutics-provides-business-update-and-reports-third-quarter-2026-financial-results.html
CRISPR Therapeutics reported strong third-quarter 2026 financial results, with CASGEVY revenue reaching $99 million, a 30% quarter-over-quarter increase. The company also announced new regulatory approvals for CASGEVY in younger patient populations in the U.K., UAE, and Bahrain, and received FDA RMAT designations for CTX310 for severe hypertriglyceridemia and elevated LDL-C. Additionally, CRISPR Therapeutics highlighted upcoming clinical data presentations and executive appointments, underscoring significant pipeline progress.
Advertisement

CRISPR Therapeutics names Sivakesava Sakhamuri as CTO

https://www.investing.com/news/company-news/crispr-therapeutics-names-sivakesava-sakhamuri-as-cto-93CH-4991656
CRISPR Therapeutics has appointed Sivakesava Sakhamuri as its new Chief Technical Officer, effective immediately. Sakhamuri brings 30 years of experience in technical operations and manufacturing leadership across various therapeutics, having previously served as CTO at Orna Therapeutics and held key roles at Omega Therapeutics and Alnylam Pharmaceuticals. His extensive background includes managing numerous Biologics License Application and Investigational New Drug submissions, contributing to eight product launches.

Eight product launches are part of the experience CRISPR Therapeutics' new technical chief brings.

https://www.stocktitan.net/news/CRSP/crispr-therapeutics-announces-the-appointment-of-siva-sakhamuri-ph-d-gdb9tpmfx0y2.html
CRISPR Therapeutics (Nasdaq: CRSP) has appointed Sivakesava (Siva) Sakhamuri, Ph.D., as its new Chief Technical Officer, effective immediately on November 2, 2026. Dr. Sakhamuri brings 30 years of experience in technical operations and manufacturing, having previously served as CTO at Orna Therapeutics and held leadership roles at Omega Therapeutics, Alnylam Pharmaceuticals, Alexion Pharmaceuticals, Sanofi Pasteur, and Bristol Myers Squibb. His extensive background includes contributing to eight product launches and managing numerous regulatory submissions, positioning him to lead CRISPR Therapeutics' technical operations as it advances its gene editing and RNA therapies.

CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer

https://uk.finance.yahoo.com/news/crispr-therapeutics-announces-appointment-siva-130000728.html
CRISPR Therapeutics has appointed Dr. Siva Sakhamuri as its new Chief Technical Officer, effective immediately. Dr. Sakhamuri brings 30 years of experience in technical operations and manufacturing across various therapeutic modalities, including biologics, RNA therapeutics, and vaccines. His appointment comes as CRISPR Therapeutics advances its gene editing and RNA therapies into late-stage clinical development, aiming to scale its technical operations and manufacturing capabilities.

CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer

https://markets.businessinsider.com/news/stocks/crispr-therapeutics-announces-the-appointment-of-siva-sakhamuri-ph-d-as-chief-technical-officer-1036700271
CRISPR Therapeutics has announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as its new Chief Technical Officer, effective immediately. Dr. Sakhamuri brings 30 years of experience in technical operations and manufacturing across various therapeutic modalities. His appointment comes as the company advances its gene editing and RNA therapies into late-stage clinical development.

CRISPR Therapeutics AG Research & Ratings | CRSP

https://www.barrons.com/market-data/stocks/crsp/research-ratings
This article provides detailed research and ratings for CRISPR Therapeutics AG (CRSP), a gene editing company. It includes analyst ratings, stock grader sentiment, key financial metrics, stock price targets, and earnings estimates for upcoming quarters and years. The consensus among analysts is a "Buy" with an average price target of $82.95.
Advertisement

CRISPR Therapeutics AG (1CG.MU) Seasonal returns chart

https://uk.finance.yahoo.com/quote/1CG.MU/seasonality/
This article presents a seasonal returns chart for CRISPR Therapeutics AG (1CG.MU), displaying the average monthly price return from 2018 to 2026. The stock's current performance is shown as 47.54 EUR, a decrease of 1.12% at the close on October 30. The content includes general market data and related tickers.

CRISPR Therapeutics AG (CRSP) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/CRSP/seasonality/
The article displays the seasonal returns chart for CRISPR Therapeutics AG (CRSP) on Yahoo Finance. It shows the average monthly price return for CRSP from 2016 to 2026. The page also includes real-time price updates and various market data related to the stock.

CRISPR Therapeutics AG (CRSP) Seasonal returns chart

https://uk.finance.yahoo.com/quote/CRSP/seasonality/
The article provides a seasonality chart for CRISPR Therapeutics AG (CRSP), noting that seasonality data is currently unavailable for the stock. It also shows the current stock price and recent trading activity, including overnight session details. The page appears to be from Yahoo Finance, indicating its typical financial information layout.

Form 4 CRISPR Therapeutics AG: Samarth Kulkarni (Director, CEO) For: 26 October

https://ng.investing.com/news/stock-market-news/form-4-crispr-therapeutics-ag-samarth-kulkarni-director-ceo-for-26-october-93CH-2765177
This article reports on a Form 4 filing for CRISPR Therapeutics AG, indicating activity involving Samarth Kulkarni, who serves as both a Director and CEO of the company. The filing pertains to October 26th. No specific details about the nature of the transaction are provided within the article.

Form 4 CRISPR Therapeutics AG: Andrew Jacob Silver (CFO) For: 26 October

https://in.investing.com/news/stock-market-news/form-4-crispr-therapeutics-ag-andrew-jacob-silver-cfo-for-26-october-93CH-5662085
This article reports on a Form 4 filing for CRISPR Therapeutics AG, specifically noting an insider transaction by Andrew Jacob Silver, the Chief Financial Officer. The filing pertains to activities on October 26. The article itself was published on October 29, 2026, at 03:50 am, according to the source.
Advertisement

The CEO receives a 28,750-share stock grant at CRISPR Therapeutics (CRSP).

https://www.stocktitan.net/sec-filings/CRSP/form-4-crispr-therapeutics-ag-insider-trading-activity-c1b6bbe32d8c.html
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, was granted a stock option for 57,500 Common Shares and restricted stock units (RSUs) for 28,750 Common Shares on October 26, 2026. The stock option has an exercise price of $49.01 per share and vests in 48 equal monthly installments starting November 26, 2026. The RSUs will vest in four equal installments annually from October 26, 2027, through October 26, 2030.

The general counsel receives a 9,000-share stock award at CRISPR Therapeutics (CRSP).

https://www.stocktitan.net/sec-filings/CRSP/form-4-crispr-therapeutics-ag-insider-trading-activity-70b91305c966.html
CRISPR Therapeutics AG's General Counsel and Secretary, James R. Kasinger, was granted two equity awards on October 26, 2026: a stock option for 18,000 Common Shares with an exercise price of $49.01, and 9,000 Restricted Stock Units. The stock option vests in 48 equal monthly installments starting November 26, 2026, while the Restricted Stock Units vest quarterly between October 26, 2027, and October 26, 2030. These awards are part of insider trading activity reported via a Form 4 filing.

CFO receives options and a stock grant tied to 9,000 shares at CRISPR Therapeutics (CRSP).

https://www.stocktitan.net/sec-filings/CRSP/form-4-crispr-therapeutics-ag-insider-trading-activity-6f19a8f40049.html
CRISPR Therapeutics AG's Chief Financial Officer, Andrew Jacob Silver, was granted 18,000 stock options with an exercise price of $49.01 per share, vesting monthly over 48 installments. Additionally, Silver received 9,000 restricted stock units, which will vest quarterly from October 2027 through October 2030. These equity awards were granted on October 26, 2026, as detailed in a recent SEC Form 4 filing.

Form 4 CRISPR Therapeutics AG For: Oct 26 Filed by: Patel Naimish

https://www.streetinsider.com/SEC+Filings/Form+4+CRISPR+Therapeutics+AG+For%3A+Oct+26+Filed+by%3A+Patel+Naimish/27250517.html
This Form 4 filing details changes in beneficial ownership for Naimish Patel, Chief Medical Officer of CRISPR Therapeutics AG (CRSP), as of October 26, 2026. The filing reports the acquisition of 24,000 stock options with a strike price of $49.01 and 12,000 restricted stock units. These equity awards have specific vesting schedules, with options vesting monthly over 48 months and RSUs vesting quarterly over four years.

Form 4 CRISPR Therapeutics AG For: Oct 26 Filed by: KASINGER JAMES R.

https://www.streetinsider.com/SEC+Filings/Form+4+CRISPR+Therapeutics+AG+For%3A+Oct+26+Filed+by%3A+KASINGER+JAMES+R./27250523.html
JAMES R. KASINGER, General Counsel and Secretary of CRISPR Therapeutics AG (CRSP), filed a Form 4 on October 28, 2026, detailing recent transactions. The filing reports the acquisition of 18,000 stock options exercisable at $49.01, vesting over 48 months, and 9,000 restricted stock units, vesting quarterly over four years. These transactions occurred on October 26, 2026.
Advertisement

Form 4 CRISPR Therapeutics AG: James R. Kasinger (General Counsel and Secretary) For: 22 September

https://ng.investing.com/news/stock-market-news/form-4-crispr-therapeutics-ag-james-r-kasinger-general-counsel-and-secretary-for-22-september-93CH-2759810
This article reports a Form 4 filing for CRISPR Therapeutics AG, detailing insider transactions by James R. Kasinger, General Counsel and Secretary, on September 22. The filing indicates a recent change in ownership for the company's stock.

CRISPR Therapeutics AG Estimates – NASDAQ:CRSP

https://www.tradingview.com/symbols/NASDAQ-CRSP/financials-estimates/
This article provides access to financial actuals and analyst estimates for CRISPR Therapeutics AG (CRSP) on TradingView. Users can explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform allows for visualization of trends over time, covering income statements, balance sheets, and cash flow information on both annual and quarterly bases.

Sensorion names CMO; Orano Med adds CSO; CRISPR Therapeutics changes CFO

https://european-biotechnology.com/latest-news/sensorion-names-cmo-orano-med-adds-cso-crispr-therapeutics-changes-cfo/
This article details recent leadership appointments across several European biotech companies. Sensorion appointed Peter Weber as CMO to prepare for clinical development of its gene therapy, while Orano Med named Matthew Fyfe as CSO to expand its pipeline of lead-212 cancer therapies. CRISPR Therapeutics saw A.J. Silver succeed Raju Prasad as CFO, as the company continues to advance its gene-editing programs.

CRISPR Therapeutics AG (CRSP) Stock Moves -1.21%: What You Should Know

https://au.finance.yahoo.com/news/crispr-therapeutics-ag-crsp-stock-210003182.html
CRISPR Therapeutics AG (CRSP) saw its stock move down 1.21% in the latest trading session, underperforming the S&P 500 and lagging the Medical sector. Analysts are predicting significant growth in EPS and revenue for the upcoming earnings release and the full year, despite recent negative revisions to consensus estimates. The company currently holds a Zacks Rank of #4 (Sell), placing it in an industry that generally outperforms.

Crispr Therapeutics AG (CRSP) Receives a Rating Update from a Top Analyst

https://www.theglobeandmail.com/investing/markets/stocks/CRSP-Q/pressreleases/8319778/crispr-therapeutics-ag-crsp-receives-a-rating-update-from-a-top-analyst/
TD Cowen analyst Tyler Van Buren maintained a Hold rating on Crispr Therapeutics AG (CRSP) with a $45.00 price target, following the company's Q2 earnings report showing $10.18 million in revenue and a $91.15 million GAAP net loss. Despite other analysts also issuing Hold or Buy ratings, corporate insider sentiment for CRSP is negative, with an increase in share sales over the last quarter.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement